Stocks-BLUE-Bluebird Bio Inc

BLUE Bluebird Bio Inc

3.31 -0.25 (-7.02%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest

Performance

-11.73% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
352.22M
Day’s Range
3.23
-
3.65
52W Range
2.78
-
8.57
Volume (3M)
4.76M
Price-Earnings Ratio
-1.93
Revenue
4.03M

Bluebird Bio Inc Latest News

View All
Top Discussions
Smart Portfolios Community
Edited
Smart Portfolio notable Gainers and Losers of 30-May-23 trading session. Top Notable Movers 👉 1. $ETRN (Equitrans Midstream Corp) gained 34.81% . Read more about it here: www.fool.com/investing/2023/05/30/why-equitrans-midstream-stock-is-skyrocketing-toda/ This asset is part of the following Smart... Show More
Smart Portfolios Community
Smart Portfolio notable Gainers and Losers of 16-May-23 trading session. Top Notable Movers 👉 1. $CNDT (Conduent Inc) gained 8.25% . Read more about it here: finance.yahoo.com/news/conduent-announces-75-million-share-124500874.html This asset is part of the following Smart Portfolios: @CarlIcahn-CF 2.... Show More
Like CommentShare
Show more comments2 of 5
null
.
Smart Portfolios Community
Smart Portfolio notable Gainers and Losers of 15-May-23 trading session. Top Notable Movers 👉 1. $SRPT (Sarepta Therapeutics Inc) gained 30.77% . Read more about it here: www.bloomberg.com/news/articles/2023-05-15/sarepta-climbs-after-fda-advisers-recommend-approval-of-dmd-gene-therapy This asset is... Show More
MarketUpdates
Edited
$BLUE (Bluebird Bio Inc) Q2 2023 earnings report is expected to be released
3
AUG
REPORTS
Bluebird Bio Inc Q2 2023 earnings report is expected to be released before market open
Notify me
BLUE
BLUE
Bluebird Bio Inc
3.31
-0.25
(-7.02%)
Trade
MarketUpdates
$BLUE (Bluebird Bio Inc) Q2 2023 earnings report is expected to be released

About Bluebird Bio Inc

Bluebird Bio Inc is an American biotechnology company based in Cambridge, Massachusetts, serving a worldwide customer base. The firm is primarily engaged in the development and commercialisation of gene therapies targeting patients with severe genetic disorders and various types of cancer. The company was founded in 1992 as Genetix Pharmaceuticals and was renamed Bluebird Bio in 2010. The firm has a strong focus on research into specific genetic diseases, including sickle cell disease, cerebral adrenoleukodystropy (CALD), and transfusion dependent beta-thalassemia. The company’s products include ZYNTEGLO (betibeglogene autotemcel) for the treatment of adult and adolescent patients with transfusion dependent beta-thalassemia, and SKYSONA (elivaldogene autotemcel) for the treatment of patients with CALD. The company has a number of products in its pipeline at various stages, from the pre-clinical stage to phase 3, all with a focus on the treatment of genetic diseases. The firm works in collaboration with various partner organisations. A research collaboration with FortySeven focuses on the development of a novel antibody-based conditioning regimen, and manufacturing agreements are in place with both Minaris and Lonza. Since 2013, the company has been a public company listed on the NASDAQ, where it trades under the ticker BLUE. Add BLUE stock to your eToro watchlist today to stay up to date on value changes.
323
Employees
Somerville, Massachusetts, US
HQ
1992
Founded
Andrew Obenshain, MBA
CEO
Show More

Upcoming Earnings

3
AUG
REPORTS
Bluebird Bio Inc Q2 2023 earnings report is expected to be released before market open

Analyst Forecast

Consensus
Moderate Sell
Price Target
4.00

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
41
Very Low
Industry 
Avg. 45 
33
Environment
49
Social
37
Governance

People Also Bought